PURAPLY ANTIMICROBIAL WOUND MATRIX
Report
- Report Number
- 1221816-2017-00003
- Event Type
- Injury
- Date Received
- April 6, 2018
- Date of Event
- July 19, 2017
- Report Date
- June 20, 2018
- Manufacturer
- ORGANOGENESIS
- Product Code
- FRO
- UDI-DI
- 00618474000039
- PMA / PMN Number
- K051647
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MA, US
- Reporter Occupation
- PHYSICIAN
Narratives
THIS SUPPLEMENTAL EMDR (FOLLOW-UP REPORT NO. 001) IS TO CORRECT INFORMATION PREVIOUSLY SUBMITTED IN EMDR MFR REPORT #1221816-2017-00003. SPECIFICALLY, THE DEVICE IDENTIFIER PORTION OF THE UNIQUE DEVICE IDENTIFIER (UDI) NUMBER LISTED IN ON THE MEDWATCH FDA FORM 3500A WAS INCORRECT. THE UDI NUMBER ON THE INITIAL EMDR SUBMISSION WAS (B)(4). THIS EMDR PROVIDES THE CORRECT UDI NUMBER FOR THE PRODUCT PURAPLY ANTIMICROBIAL WOUND MATRIX WHICH IS (B)(4). FOR THE INITIAL MDR SUBMISSION THE 'EVENT TYPE' IN H1 OF THE FDA MEDWATCH FORM 3500A WAS LISTED AS 'NO INFORMATION' BECAUSE IT IS UNCLEAR WHETHER THE EVENT THAT OCCURED RESULTED IN A SERIOUS INJURY (THIS WAS UNABLE TO BE ASSESSED DUE TO A LACK OF INFORMATION THAT WAS ABLE TO BE OBTAINED). FOR THIS SUPPLEMENTAL CORRECTION HOWEVER THE OPTION OF 'NO INFORMATION' WAS NOT ABLE TO BE SELECTED FOR 'EVENT TYPE' AND THEREFORE 'SERIOUS INJURY' WAS SELECTED, AS IT WAS THE MOST APPROPRIATE OPTION AVAILABLE (I.E. NO DEATH REPORTED, NO MALFUNCTION REPORTED). THERE ARE NO OTHER CHANGES TO THE INFORMATION CONTAINED IN THE INITIAL MDR SUBMISSION #1221816-2017-00003.
THE INFORMATION PROVIDED BY THE TREATING CLINICIAN SUGGESTS THAT IT IS POSSIBLE THAT THE INFECTION MAY HAVE BEEN RELATED TO THE APPLICATION OF PURAPLY AM, BUT WITH LIMITED INFORMATION AVAILABLE ABOUT THE EVENT, IT IS DIFFICULT TO DETERMINE WHETHER THE INFECTION WAS RELATE TO PURAPLY AM OR NOT. INFECTION IN WOUNDS CAN BE CAUSED BY A MULTITUDE OF DIFFERENT FACTORS AND IT IS ALSO NOT CLEAR WHETHER THE CELLULITIS ORIGINATED FROM THE WOUND SIRE OR ELSEWHERE. PREVIOUSLY SUBMITTED SEP 13, 2017, BUT FAILED FINAL ACKNOWLEDGEMENT, FOUND DURING FILE CLOSURE ACTIVITIES.
THE PATIENT HAD PURAPLY AM APPLIED TO A WOUND (UNKNOWN LOCATION, UNKNOWN ETIOLOGY) ON (B)(6) 2017. AT THE TIME OF THE APPLICATION, THE WOUND PRESENTED WITH SOME ERYTHEMA, AND EXCESSIVE EXUDATE, BLEEDING, ACUTE SWELLING, AND/OR INFECTION CONTROLLED. THERE WAS NO INFECTION AND BONE/TENDON WAS NOT EXPOSED. THE WOUND WAS FREE OF DEBRIS AND NECROTIC TISSUE. PURAPLY AM WAS PLACED DRY AND THEN REHYDRATED AND IN CONTACT WITH THE WOUND BED, SECURED WITH STERI-STRIPS AND COVERED WITH MEPITEL. THE PATIENT WAS TOLD TO FOLLOW UP IN ONE WEEK. ON THE PATIENTS FOLLOW UP VISIT ON (B)(6) 2017, THERE WAS EXCESSIVE REDNESS NOTED AND CELLULITIS, WHICH WAS CULTURED AND RESULTS WERE STAPH A (B)(6). ADDITIONAL INFORMATION ABOUT THE WOUND, THE CURRENT STATUS OF THE PATIENT AND OUTCOME IS UNKNOWN. WHETHER ANY MEDICAL OR SURGICAL INTERVENTION WAS REQUIRED IS UNKNOWN AND WHETHER THE PRODUCT WAS REMOVED OR REAPPLIED IS UNKNOWN.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 246605 | PURAPLY ANTIMICROBIAL WOUND MATRIX | PURAPLY ANTIMICROBIAL WOUND MATRIX | FRO | ORGANOGENESIS | 1 | AM170509.1.1D | 00618474000039 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Other |